DXCM ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against DexCom, Inc.

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its business performance and growth prospects during the specified Class Period from January 8, 2024, to July 25, 2024 [1][2]. Group 1: Allegations Against DexCom - The complaint claims that DexCom's statements about growth and anticipated margins were overly optimistic, primarily due to reliance on attracting new customers [2]. - It is alleged that DexCom faced challenges in maintaining successful existing distribution channels [2]. - As a result, the statements made by DexCom regarding its business operations and future prospects were materially false and misleading [2]. Group 2: Lead Plaintiff Process - Investors in DexCom have until October 21, 2024, to seek appointment as a lead plaintiff representative for the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - A lead plaintiff acts on behalf of all class members and typically is the investor or small group with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [5]. - The firm encourages DexCom investors who have experienced significant losses to contact them for more information [4].